VERTEX PHARMACEUTICALS INC / MA Revenues
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Revenues of $640.80 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-27.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2018-04-27
- VERTEX PHARMACEUTICALS INC / MA revenues for the quarter ending 2018-03-31 was $640.80M, a 10.34% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA revenues for the quarter ending 2017-12-31 was $651.63M, a 42.06% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA revenues for the quarter ending 2017-09-30 was $578.16M, a 39.73% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA revenues for the quarter ending 2017-06-30 was $544.13M, a 26.07% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA revenues for fiscal 2017 was $2.49B, a 46.20% increase from fiscal 2016.
- VERTEX PHARMACEUTICALS INC / MA revenues for fiscal 2016 was $1.70B, a 64.89% increase from fiscal 2015.
- VERTEX PHARMACEUTICALS INC / MA revenues for fiscal 2015 was $1.03B, a 77.86% increase from fiscal 2014.
- VERTEX PHARMACEUTICALS INC / MA revenues for fiscal 2014 was $580.41M, a 52.11% decline from fiscal 2013.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2018-03-31 | $640.80M 10-Q · filed 2018-04-27 | $1.29B derived: sum of 2 quarters · filed 2018-04-27 | $1.87B derived: sum of 3 quarters · filed 2018-04-27 | $2.41B derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-12-31 | $651.63M 10-K · filed 2018-02-15 | $1.23B derived: sum of 2 quarters · filed 2018-02-15 | $1.77B derived: sum of 3 quarters · filed 2018-02-15 | $2.49B 10-K · filed 2018-02-15 |
| 2017-09-30 | $578.16M 10-K · filed 2018-02-15 | $1.12B derived: sum of 2 quarters · filed 2018-02-15 | $1.84B 10-Q · filed 2017-10-30 | $2.30B derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-06-30 | $544.13M 10-K · filed 2018-02-15 | $1.26B 10-Q · filed 2017-07-28 | $1.72B derived: sum of 3 quarters · filed 2018-04-27 | $2.13B derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-03-31 | $714.72M 10-Q · filed 2018-04-27 | $1.17B derived: sum of 2 quarters · filed 2018-04-27 | $1.59B derived: sum of 3 quarters · filed 2018-04-27 | $2.02B derived: sum of 4 quarters · filed 2018-04-27 |
| 2016-12-31 | $458.71M 10-K · filed 2018-02-15 | $872.49M derived: sum of 2 quarters · filed 2018-02-15 | $1.30B derived: sum of 3 quarters · filed 2018-02-15 | $1.70B 10-K · filed 2018-02-15 |
| 2016-09-30 | $413.78M 10-K · filed 2018-02-15 | $845.39M derived: sum of 2 quarters · filed 2018-02-15 | $1.24B 10-Q · filed 2017-10-30 | $1.66B derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $431.61M 10-K · filed 2018-02-15 | $829.69M 10-Q · filed 2017-07-28 | $1.25B derived: sum of 3 quarters · filed 2018-02-15 | $1.56B derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $398.08M 10-K · filed 2018-02-15 | $816.01M derived: sum of 2 quarters · filed 2018-02-15 | $1.13B derived: sum of 3 quarters · filed 2018-02-15 | $1.29B derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $417.94M 10-K · filed 2017-02-23 | $727.75M derived: sum of 2 quarters · filed 2017-02-23 | $893.83M derived: sum of 3 quarters · filed 2017-02-23 | $1.03B 10-K · filed 2018-02-15 |
| 2015-09-30 | $309.82M 10-K · filed 2017-02-23 | $475.89M derived: sum of 2 quarters · filed 2017-02-23 | $614.40M 10-Q · filed 2016-10-31 | $758.96M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | $166.08M 10-K · filed 2017-02-23 | $304.58M 10-Q · filed 2016-08-01 | $449.14M derived: sum of 3 quarters · filed 2017-02-23 | $628.13M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | $138.51M 10-K · filed 2017-02-23 | $283.06M derived: sum of 2 quarters · filed 2017-02-23 | $462.05M derived: sum of 3 quarters · filed 2017-02-23 | $600.47M derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | $144.56M 10-K · filed 2016-02-16 | $323.54M derived: sum of 2 quarters · filed 2016-02-16 | $461.96M derived: sum of 3 quarters · filed 2016-02-16 | $580.41M 10-K · filed 2017-02-23 |
| 2014-09-30 | $178.99M 10-K · filed 2016-02-16 | $317.41M derived: sum of 2 quarters · filed 2016-02-16 | $435.86M 10-Q · filed 2015-10-30 | $787.02M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-06-30 | $138.42M 10-K · filed 2016-02-16 | $256.87M 10-Q · filed 2015-08-04 | $608.03M derived: sum of 3 quarters · filed 2016-02-16 | $829.73M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-03-31 | $118.45M 10-K · filed 2016-02-16 | $469.61M derived: sum of 2 quarters · filed 2016-02-16 | $691.31M derived: sum of 3 quarters · filed 2016-02-16 | $1.00B derived: sum of 4 quarters · filed 2016-02-16 |
| 2013-12-31 | $351.16M 10-K · filed 2015-02-13 | $572.86M derived: sum of 2 quarters · filed 2015-02-13 | $883.61M derived: sum of 3 quarters · filed 2015-02-13 | $1.21B 10-K · filed 2016-02-16 |
| 2013-09-30 | $221.70M 10-K · filed 2015-02-13 | $532.45M derived: sum of 2 quarters · filed 2015-02-13 | $860.82M 10-Q · filed 2014-11-06 | $1.19B derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $310.75M 10-K · filed 2015-02-13 | $639.12M 10-Q · filed 2014-07-31 | $973.11M derived: sum of 3 quarters · filed 2015-02-13 | $1.31B derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $328.37M 10-K · filed 2015-02-13 | $662.36M derived: sum of 2 quarters · filed 2015-02-13 | $998.37M derived: sum of 3 quarters · filed 2015-02-13 | $1.42B derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $333.99M 10-K · filed 2014-02-11 | $670.00M derived: sum of 2 quarters · filed 2014-02-11 | $1.09B derived: sum of 3 quarters · filed 2014-02-11 | $1.53B 10-K · filed 2015-02-13 |
| 2012-09-30 | $336.01M 10-K · filed 2014-02-11 | $754.31M derived: sum of 2 quarters · filed 2014-02-11 | $1.19B 10-Q · filed 2013-11-07 | $1.76B derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | $418.31M 10-K · filed 2014-02-11 | $857.04M 10-Q · filed 2013-08-02 | $1.42B derived: sum of 3 quarters · filed 2014-02-11 | $2.08B derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | $438.74M 10-K · filed 2014-02-11 | $1.00B derived: sum of 2 quarters · filed 2014-02-11 | $1.66B derived: sum of 3 quarters · filed 2014-02-11 | $1.78B derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | $563.34M 10-K · filed 2013-03-01 | $1.22B derived: sum of 2 quarters · filed 2013-03-01 | $1.34B derived: sum of 3 quarters · filed 2013-03-01 | $1.41B 10-K · filed 2014-02-11 |
| 2011-09-30 | $659.20M 10-K · filed 2013-03-01 | $773.62M derived: sum of 2 quarters · filed 2013-03-01 | $847.29M 10-Q · filed 2012-11-06 | $912.81M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $114.42M 10-K · filed 2013-03-01 | $188.09M 10-Q · filed 2012-08-08 | $253.61M derived: sum of 3 quarters · filed 2013-03-01 | $277.40M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $73.66M 10-K · filed 2013-03-01 | $139.19M derived: sum of 2 quarters · filed 2013-03-01 | $162.98M derived: sum of 3 quarters · filed 2013-03-01 | $194.60M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $65.52M 10-K · filed 2012-02-22 | $89.32M derived: sum of 2 quarters · filed 2012-02-22 | $120.94M derived: sum of 3 quarters · filed 2012-02-22 | $143.37M 10-K · filed 2013-03-01 |
| 2010-09-30 | $23.80M 10-K · filed 2012-02-22 | $55.42M derived: sum of 2 quarters · filed 2012-02-22 | $77.85M 10-Q · filed 2011-11-03 | $111.73M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-06-30 | $31.62M 10-K · filed 2012-02-22 | $54.05M 10-Q · filed 2011-08-09 | $87.94M derived: sum of 3 quarters · filed 2012-02-22 | $112.90M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-03-31 | $22.43M 10-K · filed 2012-02-22 | $56.32M derived: sum of 2 quarters · filed 2012-02-22 | $81.28M derived: sum of 3 quarters · filed 2012-02-22 | $100.34M derived: sum of 4 quarters · filed 2012-02-22 |
| 2009-12-31 | $33.89M 10-K · filed 2011-02-17 | $58.85M derived: sum of 2 quarters · filed 2011-02-17 | $77.91M derived: sum of 3 quarters · filed 2011-02-17 | $101.89M 10-K · filed 2012-02-22 |
| 2009-09-30 | $24.96M 10-K · filed 2011-02-17 | $44.02M derived: sum of 2 quarters · filed 2011-02-17 | $68.00M 10-Q · filed 2010-10-28 | |
| 2009-06-30 | $19.06M 10-K · filed 2011-02-17 | $43.04M 10-Q · filed 2010-08-03 | ||
| 2009-03-31 | $23.98M 10-K · filed 2011-02-17 | |||
| 2008-12-31 | $175.50M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |